Improving diversity in clinical trials is not just the right thing to do, it is necessary for better science, more representative outcomes, and increased health equity. Historically, clinical trials have been shown to recruit disproportionately large percentages of White participants. These skewed participant populations raise concerns about the generalizability of trial results to underrepresented non-White participants and inequitable access to clinical trial treatments. The FDA published updated guidance to address these concerns in April 2022, stating that clinical trial participants need to reflect the demographic distribution of the United States (US) population.
Download to find out more.